# Research Proposal: Reinforcement Learning from Biological Feedback for Genomics Foundation Models

## 1. Title

**Reinforcement Learning from Biological Feedback (RLBF): Aligning Genomics Foundation Models with Experimental Outcomes for Perturbation Prediction**

## 2. Introduction

### 2.1 Background

The pharmaceutical industry faces a critical challenge: approximately 90% of drug candidates fail in clinical trials, with a significant proportion of failures attributed to inadequate understanding of biological mechanisms and poor prediction of real-world therapeutic outcomes. This translates to billions of dollars in wasted investment and delayed treatments for patients. Recent advances in genomics platforms have generated unprecedented volumes of perturbation data—including the LINCS L1000 dataset with 1.3 million perturbation profiles—yet our computational models struggle to translate these data into reliable predictions of experimental success.

Foundation models for genomics, such as scGPT, represent a paradigm shift in biological sequence analysis. Pretrained on 33 million single-cell RNA-seq profiles, scGPT has demonstrated state-of-the-art performance on tasks including cell type annotation, batch integration, and perturbation response prediction. However, current fine-tuning approaches rely exclusively on supervised learning, which optimizes models to fit labeled training data rather than to maximize experimental success in real-world applications. This fundamental limitation creates a gap between computational predictions and biological reality.

In natural language processing, Reinforcement Learning from Human Feedback (RLHF) has revolutionized large language model alignment, enabling models like ChatGPT to generate outputs that better satisfy human preferences and intentions. The core insight of RLHF is that complex objectives—such as helpfulness, harmlessness, and honesty—are difficult to capture through supervised labels alone but can be learned through preference comparisons and reward-based optimization. We propose adapting this paradigm to genomics by replacing human feedback with **biological feedback** from experimental outcomes.

### 2.2 Research Objectives

This research aims to develop and validate a novel framework—Reinforcement Learning from Biological Feedback (RLBF)—that aligns genomics foundation models with experimental outcomes through reward-based policy optimization. Our specific objectives are:

1. **Develop an ensemble biological reward model** that learns to predict experimental success from pairwise comparisons of successful versus failed perturbations in the LINCS L1000 dataset, augmented with validated computational biological constraint metrics (drug-likeness, binding affinity, synthetic accessibility).

2. **Implement PPO-based policy optimization** for scGPT that maximizes expected biological reward while preserving pretrained knowledge through KL-divergence regularization, enabling the model to iteratively improve perturbation predictions based on experimental success signals.

3. **Validate the RLBF framework** through comprehensive evaluation on 130,000 held-out perturbation predictions and 200 experimental validations, demonstrating ≥5% improvement in prediction accuracy and ≥10% improvement in experimental validation rates compared to supervised fine-tuning baselines.

4. **Establish design principles** for applying reinforcement learning to genomics foundation models, including reward function construction, hyperparameter selection, and strategies to prevent catastrophic forgetting of pretrained biological knowledge.

### 2.3 Research Hypothesis

**Main Hypothesis:** Under genomics foundation model fine-tuning conditions with LINCS L1000 perturbation data, if reinforcement learning from biological feedback (RLBF) with ensemble reward models is applied to scGPT via PPO policy optimization with KL regularization, then perturbation prediction accuracy and biological validity scores will exceed supervised fine-tuning (SFT) adapter baselines by statistically significant margins (≥5% accuracy gain, p<0.05) because reward-based policy optimization aligns model predictions with experimental outcomes and biological constraints through iterative learning from success/failure signals.

**Mechanistic Rationale:** The causal pathway operates through five key steps: (1) construction of pairwise comparison datasets from LINCS efficacy outcomes, (2) training of ensemble Bradley-Terry reward models to predict biological validity, (3) PPO policy optimization that updates scGPT weights to maximize expected reward, (4) KL regularization that prevents catastrophic forgetting of pretrained knowledge, and (5) improved alignment between predictions and experimental outcomes. This mechanism differs fundamentally from supervised fine-tuning, which optimizes for fitting labeled data rather than maximizing experimental success.

### 2.4 Significance

This research addresses a critical gap in computational drug discovery: the misalignment between model optimization objectives and real-world experimental outcomes. The significance spans multiple dimensions:

**Scientific Impact:** RLBF establishes a new paradigm for training genomics foundation models that directly optimizes for experimental success rather than supervised label fitting. This represents the first application of RLHF principles to genomics at scale, potentially catalyzing a broader shift toward reward-based optimization in computational biology.

**Practical Impact:** By improving perturbation prediction accuracy by ≥5% and experimental validation rates by ≥10%, RLBF could substantially reduce the cost and time required for target identification in drug discovery. Even modest improvements in prediction accuracy translate to millions of dollars saved by avoiding failed experimental validations and clinical trials.

**Methodological Impact:** The ensemble biological reward model framework provides a generalizable approach for incorporating experimental feedback into foundation model training. The design principles established through this work—including reward function construction, hyperparameter selection, and catastrophic forgetting prevention—will inform future applications of RL to genomics tasks beyond perturbation prediction.

**Broader Impact:** Success of this framework could accelerate the development of gene therapies, RNA-based drugs, and personalized medicine approaches by enabling more accurate computational prediction of therapeutic outcomes. The methodology is particularly relevant for emerging drug modalities where experimental validation is expensive and time-consuming.

## 3. Methodology

### 3.1 Overall Research Design

The research follows a four-phase experimental design: (1) data preparation and reward model development, (2) RLBF implementation and training, (3) comprehensive evaluation on held-out test sets, and (4) experimental validation. Each phase includes rigorous controls and ablation studies to isolate the contribution of the RLBF mechanism.

### 3.2 Data Collection and Preparation

#### 3.2.1 Primary Dataset: LINCS L1000

We utilize the LINCS L1000 dataset, which contains 1,319,138 gene expression profiles measuring cellular responses to chemical and genetic perturbations across multiple cancer cell lines. The dataset provides:

- **Perturbation profiles:** Gene expression measurements for 978 landmark genes
- **Experimental metadata:** Cell line identity, perturbation type (compound or genetic), dose, time point
- **Efficacy outcomes:** Z-scores quantifying perturbation effect magnitude

**Data Partitioning:**
- Training set: 1,170,000 profiles (88.7%)
- Validation set: 65,000 profiles (4.9%)
- Held-out test set: 130,000 profiles (9.9%)

Partitioning ensures no compound or cell line overlap between training and test sets to evaluate generalization.

#### 3.2.2 Pairwise Comparison Dataset Construction

To train the biological reward model, we construct pairwise comparisons from LINCS efficacy outcomes:

**Success/Failure Labeling:**
- **Successful perturbations:** Top 20% by efficacy z-score (z > 1.28, corresponding to p < 0.10 one-tailed)
- **Failed perturbations:** Bottom 20% by efficacy z-score (z < -1.28)

This yields approximately 250,000 balanced pairwise comparisons of the form $(p_{\text{success}}, p_{\text{failure}})$, where each pair represents perturbations with contrasting experimental outcomes.

**Composite Success Criteria:**
To address potential ambiguity in efficacy-only labels (e.g., high efficacy but high toxicity), we incorporate toxicity data where available:
- Success requires efficacy z-score > 1.28 AND toxicity < 20% (if toxicity data available)
- Failure defined as efficacy z-score < -1.28 OR toxicity > 50%

#### 3.2.3 Biological Constraint Metrics

We compute three established biological validity metrics for each perturbation:

1. **QED (Quantitative Estimate of Drug-likeness):** Measures drug-likeness based on molecular properties (molecular weight, logP, hydrogen bond donors/acceptors, etc.). Range: [0, 1], threshold for validity: QED > 0.6.

2. **Binding Affinity (AutoDock Vina):** Predicts protein-ligand binding energy for target proteins relevant to each perturbation. Measured in kcal/mol, threshold: < -7 kcal/mol indicates strong binding.

3. **SAScore (Synthetic Accessibility Score):** Estimates ease of chemical synthesis. Range: [1, 10], threshold: < 6 indicates reasonable synthetic accessibility.

**Pilot Validation Study:**
Before incorporating these metrics into the reward function, we conduct a pilot study on 1,000 randomly sampled LINCS perturbations to validate correlation with experimental success:

$$r_{\text{metric}} = \text{Pearson}(\text{metric\_score}, \text{experimental\_success})$$

Metrics are included in the reward function only if $r_{\text{metric}} > 0.5$. This empirical validation ensures biological constraints provide meaningful signal for experimental outcomes.

### 3.3 Biological Reward Model Development

#### 3.3.1 Bradley-Terry Model Formulation

We employ the Bradley-Terry model, a probabilistic framework for learning preferences from pairwise comparisons. For perturbations $p_i$ and $p_j$, the probability that $p_i$ is preferred (more successful) over $p_j$ is:

$$P(p_i \succ p_j) = \frac{\exp(r_\theta(p_i))}{\exp(r_\theta(p_i)) + \exp(r_\theta(p_j))} = \sigma(r_\theta(p_i) - r_\theta(p_j))$$

where $r_\theta(p)$ is the reward function parameterized by neural network weights $\theta$, and $\sigma$ is the sigmoid function.

**Neural Network Architecture:**
The reward model $r_\theta$ takes as input the perturbation representation from scGPT's encoder (768-dimensional embedding) and outputs a scalar reward score:

- Input layer: 768-dimensional perturbation embedding from scGPT
- Hidden layers: 2 fully connected layers (512 → 256 units) with ReLU activation and dropout (p=0.2)
- Output layer: Single scalar reward value

**Training Objective:**
The reward model is trained to maximize log-likelihood of observed pairwise preferences:

$$\mathcal{L}_{\text{reward}} = -\frac{1}{N} \sum_{i=1}^{N} \log P(p_i^{\text{success}} \succ p_i^{\text{failure}})$$

where $N = 250,000$ is the number of pairwise comparisons.

#### 3.3.2 Ensemble Reward Model

To reduce overfitting and improve robustness, we train an ensemble of 5 Bradley-Terry models with different random initializations and data bootstrap samples:

$$R_{\text{ensemble}}(p) = \frac{1}{5} \sum_{k=1}^{5} r_{\theta_k}(p)$$

**Ensemble Validation Criteria:**
- Validation AUC > 0.75 (discriminative ability to distinguish successful vs. failed perturbations)
- Inter-model agreement > 70% (Pearson correlation between individual model predictions)
- Standard deviation across ensemble < 0.3 (reward signal stability)

#### 3.3.3 Composite Reward Function

The final reward function combines ensemble predictions with validated biological constraint metrics:

$$R(p) = \alpha \cdot R_{\text{ensemble}}(p) + \beta \cdot \mathbb{I}[\text{QED}(p) > 0.6] + \gamma \cdot \mathbb{I}[\text{Binding}(p) < -7] + \delta \cdot \mathbb{I}[\text{SAScore}(p) < 6]$$

where $\mathbb{I}[\cdot]$ is the indicator function, and weights $\{\alpha, \beta, \gamma, \delta\}$ are tuned on the validation set. Biological constraint terms are included only if pilot study shows $r > 0.5$ correlation with experimental success.

### 3.4 RLBF Implementation: PPO Policy Optimization

#### 3.4.1 Policy Formulation

We formulate perturbation prediction as a sequential decision problem where the policy $\pi_\phi$ (parameterized by scGPT weights $\phi$) generates gene expression predictions conditioned on perturbation context:

$$\pi_\phi(y | x) = P_{\text{scGPT}}(\text{perturbed\_expression} | \text{baseline\_expression}, \text{perturbation\_context})$$

The policy outputs a distribution over gene expression values for 978 landmark genes.

#### 3.4.2 Proximal Policy Optimization (PPO)

PPO optimizes the policy to maximize expected reward while constraining policy updates to prevent instability:

**Objective Function:**

$$\mathcal{L}_{\text{PPO}}(\phi) = \mathbb{E}_{(x,y) \sim \pi_\phi} \left[ \min\left( \frac{\pi_\phi(y|x)}{\pi_{\phi_{\text{old}}}(y|x)} A^{\pi_{\phi_{\text{old}}}}(x,y), \text{clip}\left(\frac{\pi_\phi(y|x)}{\pi_{\phi_{\text{old}}}(y|x)}, 1-\epsilon, 1+\epsilon\right) A^{\pi_{\phi_{\text{old}}}}(x,y) \right) \right]$$

where:
- $A^{\pi_{\phi_{\text{old}}}}(x,y)$ is the advantage function estimating how much better action $y$ is than average
- $\epsilon = 0.2$ is the clipping parameter preventing large policy updates
- $\pi_{\phi_{\text{old}}}$ is the policy from the previous iteration

**Advantage Estimation:**
We use Generalized Advantage Estimation (GAE) with $\lambda = 0.95$:

$$A^{\pi}(x,y) = \sum_{t=0}^{T} (\gamma \lambda)^t \delta_t$$

where $\delta_t = R(p_t) + \gamma V(x_{t+1}) - V(x_t)$ and $V(x)$ is a learned value function.

#### 3.4.3 KL Regularization for Catastrophic Forgetting Prevention

To preserve pretrained biological knowledge, we add a KL-divergence penalty between the current policy $\pi_\phi$ and the pretrained policy $\pi_{\phi_0}$:

$$\mathcal{L}_{\text{total}}(\phi) = \mathcal{L}_{\text{PPO}}(\phi) - \beta \cdot \mathbb{E}_{x} \left[ D_{\text{KL}}(\pi_\phi(\cdot|x) \| \pi_{\phi_0}(\cdot|x)) \right]$$

**KL Coefficient Tuning:**
We evaluate $\beta \in \{0.01, 0.02, 0.05\}$ on the validation set, selecting the value that maximizes perturbation prediction accuracy while maintaining < 5% performance degradation on original scGPT tasks (cell type annotation, batch integration).

#### 3.4.4 Training Procedure

**Algorithm: RLBF Training**

```
Input: Pretrained scGPT model π_φ₀, reward model R, LINCS training data D_train
Output: Optimized policy π_φ*

1. Initialize policy π_φ ← π_φ₀
2. For epoch = 1 to N_epochs:
   3. Sample batch of perturbations {x₁, ..., x_B} from D_train
   4. Generate predictions {y₁, ..., y_B} ~ π_φ(·|x)
   5. Compute rewards {R(p₁), ..., R(p_B)}
   6. Compute advantages {A₁, ..., A_B} using GAE
   7. Update policy using PPO objective with KL regularization:
      φ ← φ + α∇_φ L_total(φ)
   8. Evaluate on validation set:
      - Perturbation prediction accuracy
      - Original task performance (cell type annotation)
   9. If validation accuracy plateaus for 5 epochs: break
   10. If original task performance degrades > 5%: reduce β and restart
11. Return π_φ*
```

**Hyperparameters:**
- Learning rate: $\alpha = 1 \times 10^{-5}$
- Batch size: 32 perturbations
- PPO epochs per batch: 4
- Discount factor: $\gamma = 0.99$
- GAE parameter: $\lambda = 0.95$
- Clipping parameter: $\epsilon = 0.2$
- KL coefficient: $\beta \in \{0.01, 0.02, 0.05\}$ (tuned on validation)
- Total training epochs: 100 (with early stopping)

### 3.5 Baseline Methods

#### 3.5.1 Supervised Fine-Tuning (SFT) Adapter Baseline

We implement the adapter-based fine-tuning approach from Maleki et al. (2024), which achieves state-of-the-art zero-shot perturbation prediction:

- **Architecture:** Low-rank adapter layers inserted into scGPT transformer blocks
- **Training:** Supervised learning on LINCS perturbation-response pairs
- **Objective:** Mean squared error between predicted and actual gene expression

$$\mathcal{L}_{\text{SFT}} = \frac{1}{N} \sum_{i=1}^{N} \|y_i^{\text{pred}} - y_i^{\text{true}}\|^2$$

#### 3.5.2 Bayesian Optimization (BO) Baseline

To address the comparison with LaMBO (Stanton et al., 2022), we implement a Bayesian Optimization baseline:

- **Acquisition function:** Expected Improvement (EI) in latent space
- **Surrogate model:** Gaussian Process over scGPT embeddings
- **Optimization:** Sequential selection of perturbations to maximize predicted reward

This baseline tests whether RL's iterative policy optimization provides advantages over BO's explore-exploit tradeoff.

### 3.6 Evaluation Metrics

#### 3.6.1 Primary Metric: Perturbation Prediction Accuracy

**Pearson Correlation:**
For each perturbation in the test set, we compute the Pearson correlation between predicted and actual gene expression profiles across 978 landmark genes:

$$\text{Accuracy} = \frac{1}{N_{\text{test}}} \sum_{i=1}^{N_{\text{test}}} \text{Pearson}(y_i^{\text{pred}}, y_i^{\text{true}})$$

where $N_{\text{test}} = 130,000$ held-out perturbations.

**Statistical Testing:**
- **Method:** Paired t-test comparing RLBF vs. SFT accuracy across 20 independent runs (different random seeds)
- **Null hypothesis:** $H_0: \mu_{\text{RLBF}} - \mu_{\text{SFT}} \leq 0$
- **Alternative hypothesis:** $H_1: \mu_{\text{RLBF}} - \mu_{\text{SFT}} > 0.05$ (5% improvement)
- **Significance level:** $\alpha = 0.05$ (one-tailed test)
- **Effect size:** Cohen's d for standardized mean difference

#### 3.6.2 Secondary Metrics

**Biological Validity Score:**
Percentage of predictions meeting all three biological constraint thresholds:

$$\text{BioValidity} = \frac{1}{N_{\text{test}}} \sum_{i=1}^{N_{\text{test}}} \mathbb{I}[\text{QED}(p_i) > 0.6 \land \text{Binding}(p_i) < -7 \land \text{SAScore}(p_i) < 6]$$

**Experimental Validation Success Rate:**
For 200 selected perturbations (100 from RLBF, 100 from SFT), we measure:

$$\text{ExpSuccess} = \frac{\text{Number of perturbations with efficacy > 1.5× control AND toxicity < 20\%}}{\text{Total perturbations tested}}$$

**Catastrophic Forgetting Assessment:**
Performance on original scGPT tasks before and after RLBF training:
- Cell type annotation accuracy (10-class classification on held-out cells)
- Batch integration quality (silhouette score on integrated embeddings)

Acceptable degradation threshold: < 5% relative decrease.

### 3.7 Experimental Validation Protocol

#### 3.7.1 Perturbation Selection Strategy

From the 130,000 test set predictions, we select 200 perturbations for experimental validation using stratified sampling:

- **Top-ranked RLBF predictions:** 50 perturbations with highest predicted reward
- **Top-ranked SFT predictions:** 50 perturbations with highest predicted efficacy
- **Disagreement cases:** 50 perturbations where RLBF and SFT predictions diverge most
- **Random baseline:** 50 randomly selected perturbations

This strategy enables head-to-head comparison while exploring cases where methods disagree.

#### 3.7.2 Validation Approach

**Phase 1: High-Fidelity Simulation (Weeks 1-4)**
- Molecular dynamics simulations for binding affinity validation
- ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) prediction using physics-based models
- Provides rapid feedback for 200 perturbations

**Phase 2: Experimental Validation (Months 2-4, contingent on lab partnership)**
- Top 50 perturbations from Phase 1 tested in cancer cell line assays
- Efficacy measured via cell viability assays (IC50 determination)
- Toxicity assessed via cytotoxicity assays on healthy cell lines

### 3.8 Ablation Studies

To isolate the contribution of each RLBF component, we conduct systematic ablation studies:

**Ablation 1: Reward Function Components**
- RLBF with ensemble reward only (no biological constraints)
- RLBF with biological constraints only (no learned reward)
- RLBF with full composite reward

**Ablation 2: KL Regularization Strength**
- $\beta = 0$ (no KL penalty, risk of catastrophic forgetting)
- $\beta \in \{0.005, 0.01, 0.02, 0.05, 0.1\}$
- Measure trade-off between reward maximization and pretrained knowledge preservation

**Ablation 3: Ensemble Size**
- Single reward model vs. ensemble of {3, 5, 7} models
- Assess impact on reward signal stability and generalization

### 3.9 Computational Resources

**Training Infrastructure:**
- 8× NVIDIA A100 GPUs (80GB memory each)
- Estimated training time: 140 GPU-hours per run
- Total compute for 20 runs: 2,800 GPU-hours (parallelizable across cluster)

**Software Stack:**
- PyTorch 2.0 for model implementation
- Stable-Baselines3 for PPO implementation
- Hugging Face Transformers for scGPT integration
- RDKit for molecular property calculations
- AutoDock Vina for binding affinity prediction

### 3.10 Reproducibility Measures

- **Fixed random seeds:** All experiments use documented random seeds for reproducibility
- **Hyperparameter logging:** MLflow tracks all hyperparameters, metrics, and model checkpoints
- **Code release:** Full implementation released on GitHub with Docker containers for environment reproducibility
- **Data versioning:** LINCS dataset version and preprocessing scripts documented
- **Deterministic operations:** PyTorch deterministic mode enabled for reproducible GPU operations

## 4. Expected Outcomes & Impact

### 4.1 Expected Outcomes

#### 4.1.1 Primary Outcome: Superior Perturbation Prediction Accuracy

We expect RLBF-optimized scGPT to achieve **≥5% higher perturbation prediction accuracy** compared to SFT adapter baselines on the 130,000 held-out LINCS test set, with statistical significance (p < 0.05, paired t-test across 20 independent runs). Specifically:

- **SFT baseline accuracy:** 72-75% (Pearson correlation, based on Maleki et al. 2024 results)
- **RLBF target accuracy:** 77-80% (5-8 percentage point improvement)
- **Effect size:** Cohen's d ≈ 2.5 (large effect, assuming ~2% standard deviation)

This improvement represents a meaningful advance in genomics ML, where 3-10% accuracy gains are considered significant given the complexity of biological systems.

#### 4.1.2 Secondary Outcome: Enhanced Biological Validity

RLBF predictions are expected to achieve **≥10% higher biological validity scores** compared to SFT baselines:

- **SFT baseline:** 45-50% of predictions meeting all three biological constraint thresholds
- **RLBF target:** 55-60% of predictions meeting thresholds
- **Mechanism:** Explicit reward optimization for biological constraints drives the model toward drug-like, synthetically accessible compounds with favorable binding properties

#### 4.1.3 Tertiary Outcome: Improved Experimental Validation Success

In the 200-perturbation experimental validation study, we expect:

- **SFT baseline success rate:** 55-60% (perturbations achieving efficacy >1.5× control AND toxicity <20%)
- **RLBF success rate:** 65-70% (≥10 percentage point improvement)
- **Statistical significance:** Chi-square test, p < 0.05

This outcome directly addresses the core motivation: bridging the gap between computational predictions and biological reality.

#### 4.1.4 Mechanistic Insights

Ablation studies will reveal:

1. **Reward function contribution:** Quantify the relative importance of learned ensemble rewards vs. biological constraint metrics
2. **KL regularization trade-off:** Identify optimal $\beta$ values that balance reward maximization with pretrained knowledge preservation
3. **Ensemble benefit:** Demonstrate whether ensemble reward models provide robustness advantages over single models

### 4.2 Potential Challenges and Mitigation Strategies

#### 4.2.1 Challenge: Reward Model Overfitting

**Risk:** Ensemble reward models may overfit to LINCS pairwise comparisons, failing to generalize to novel perturbations.

**Mitigation:**
- Regularization through ensemble diversity (different bootstrap samples)
- Validation on external dataset (GDSC drug response data)
- Early stopping based on validation AUC

**Contingency:** If validation AUC < 0.75, increase pairwise comparison dataset size or simplify reward model architecture (linear features instead of neural network).

#### 4.2.2 Challenge: Catastrophic Forgetting

**Risk:** PPO optimization may degrade scGPT's pretrained capabilities (cell type annotation, batch integration).

**Mitigation:**
- KL regularization with tuned $\beta$ coefficient
- Continuous monitoring of original task performance during training
- Early stopping if degradation exceeds 5%

**Contingency:** If catastrophic forgetting occurs despite KL regularization, switch to adapter-based RL (freeze scGPT backbone, optimize only adapter layers).

#### 4.2.3 Challenge: Experimental Validation Logistics

**Risk:** Real lab experiments have 4-8 week latency, potentially delaying validation.

**Mitigation:**
- Phase 1 validation using high-fidelity physics-based simulations (2-4 week turnaround)
- Parallel execution of simulation and lab experiments
- Prioritize top-performing perturbations for lab validation

**Contingency:** If lab partnership is unavailable, rely on simulation validation with external dataset cross-validation (GDSC, ChEMBL).

### 4.3 Scientific Impact

#### 4.3.1 Paradigm Shift in Genomics Foundation Model Training

RLBF establishes a new training paradigm that optimizes directly for experimental success rather than supervised label fitting. This represents the first large-scale application of RLHF principles to genomics, potentially catalyzing broader adoption of reward-based optimization in computational biology.

**Key Innovation:** Demonstrating that biological feedback can serve as a training signal analogous to human feedback in NLP, opening new avenues for incorporating experimental outcomes into model training loops.

#### 4.3.2 Methodological Contributions

The research contributes generalizable methodologies:

1. **Ensemble biological reward models:** Framework for learning experimental success predictors from pairwise comparisons
2. **KL-regularized policy optimization:** Strategies for preventing catastrophic forgetting in foundation model fine-tuning
3. **Composite reward functions:** Principled approach for combining learned rewards with domain-specific constraints

These methods extend beyond perturbation prediction to other genomics tasks (protein design, gene therapy optimization, drug combination prediction).

#### 4.3.3 Benchmark and Dataset Contributions

We will release:
- **LINCS-RLBF benchmark:** Standardized train/validation/test splits with pairwise comparison labels
- **Reward model checkpoints:** Pretrained ensemble reward models for community use
- **Experimental validation dataset:** 200 perturbations with simulation and lab validation results

### 4.4 Practical Impact on Drug Discovery

#### 4.4.1 Accelerated Target Identification

Improved perturbation prediction accuracy (≥5%) translates to:
- **Reduced experimental screening:** Fewer compounds require wet-lab validation
- **Cost savings:** Estimated $500K-$1M per drug discovery program (assuming 20% reduction in failed experiments)
- **Time savings:** 3-6 months faster target identification timelines

#### 4.4.2 Enhanced Success Rates for Emerging Modalities

RLBF is particularly valuable for emerging drug modalities (gene therapies, RNA-based drugs, cell therapies) where:
- Experimental validation is expensive ($10K-$100K per candidate)
- Clinical trial failure rates are high (>90%)
- Computational prediction accuracy is currently limited

A 10% improvement in experimental validation success rate could save millions of dollars per therapeutic program.

#### 4.4.3 Personalized Medicine Applications

The framework enables:
- **Patient-specific perturbation prediction:** Fine-tune RLBF on individual patient genomic profiles
- **Combination therapy optimization:** Predict synergistic drug combinations using multi-perturbation reward models
- **Adverse event prediction:** Incorporate toxicity outcomes into reward function for safety-focused optimization

### 4.5 Broader Impact on Machine Learning for Science

#### 4.5.1 Cross-Domain Applicability

The RLBF framework generalizes to other scientific domains where:
- Foundation models exist (materials science, climate modeling, protein engineering)
- Experimental feedback is available but expensive
- Supervised labels are insufficient to capture complex objectives

**Example Applications:**
- **Materials science:** Optimize generative models for synthesizable materials with desired properties
- **Protein engineering:** Align protein language models with experimental fitness landscapes
- **Climate modeling:** Incorporate observational data as rewards for weather prediction models

#### 4.5.2 Advancing Human-AI Collaboration in Science

RLBF demonstrates a new mode of human-AI collaboration where:
- Computational models propose candidates (perturbations, molecules, materials)
- Experimental scientists provide feedback (success/failure outcomes)
- Models iteratively improve through closed-loop learning

This paradigm could transform scientific discovery by enabling tighter integration between computational prediction and experimental validation.

### 4.6 Limitations and Future Directions

#### 4.6.1 Current Scope Limitations

- **Perturbation type:** Limited to small-molecule compounds (LINCS scope); does not cover CRISPR/genetic perturbations
- **Cell type:** Focused on cancer cell lines; generalization to healthy tissues requires domain adaptation
- **Feedback latency:** Real experiments have weeks-to-months delay; future work should explore active learning strategies for efficient feedback collection

#### 4.6.2 Future Research Directions

1. **Multi-modal RLBF:** Extend to multi-omics data (proteomics, metabolomics, imaging) for richer reward signals
2. **Active learning integration:** Develop acquisition functions for selecting most informative perturbations for experimental validation
3. **Causal reward models:** Incorporate causal inference to distinguish correlation from causation in experimental outcomes
4. **Federated RLBF:** Enable collaborative training across institutions while preserving data privacy
5. **Real-time clinical applications:** Develop low-latency RLBF variants for time-sensitive therapeutic decisions

### 4.7 Dissemination and Community Engagement

**Publications:**
- Primary research paper submitted to ICLR 2025 Workshop on Machine Learning for Genomics Explorations (Special Track on LLMs and Agentic AI)
- Follow-up journal article in *Nature Machine Intelligence* or *Cell Systems*

**Open-Source Release:**
- GitHub repository with full implementation, documentation, and tutorials
- Pretrained model checkpoints on Hugging Face Model Hub
- Interactive demo for perturbation prediction

**Community Workshops:**
- Tutorial at NeurIPS 2025 on "Reinforcement Learning for Scientific Discovery"
- Invited talks at genomics and ML conferences (ISMB, ICML, ICLR)

**Industry Partnerships:**
- Collaboration with pharmaceutical companies for real-world validation
- Technology transfer for integration into drug discovery pipelines

---

**Conclusion:**

This research proposes a transformative approach to aligning genomics foundation models with experimental outcomes through Reinforcement Learning from Biological Feedback (RLBF). By adapting RLHF principles from natural language processing to genomics, we address a critical gap in computational drug discovery: the misalignment between model optimization objectives and real-world biological success. The expected outcomes—≥5% improvement in prediction accuracy, ≥10% improvement in experimental validation rates, and establishment of generalizable design principles—have the potential to accelerate target identification, reduce drug discovery costs, and advance personalized medicine. Beyond genomics, RLBF establishes a paradigm for incorporating experimental feedback into foundation model training across scientific domains, catalyzing a new era of human-AI collaboration in scientific discovery.